Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:58 AM
Ignite Modification Date:
2025-12-24 @ 11:58 AM
NCT ID:
NCT05225961
Eligibility Criteria:
Inclusion Criteria:
* Patients with acute ischemic stroke of the anterior territory secondary to a tandem lesion, with an indication for thrombectomy treatment according to the current recommendations of the Clinical Practice Guidelines, and the need for cervical stent placement.
* The intracranial occlusion locations that may be included are: carotid "T", M1 and M2 segments of the middle cerebral artery, segment A1 of the anterior cerebral artery; and in the case that the posterior cerebral artery has fetal origin and is the site of intracranial occlusion.
* ASPECTS (Alberta Stroke Program Early computerized Tomography Score) ≥6.
* Greater than or equal to 18 years of age.
* Signed informed consent.
Exclusion Criteria:
* Patients under 18 years of age.
* Patients with ASPECTS \<6.
* Bilateral strokes or those produced by simultaneous occlusion of an artery in the anterior and posterior territory.
* Patients whose carotid stenosis is due to a re-stenosis or reocclusion of a pre-existing cervical stent.
* Candidate patients for carotid puncture.
* Previous treatment with double antiplatelet therapy for another cause prior to inclusion.
* Severe comorbidity and / or reduced life expectancy.
* Modified Rankin scale (mRS)\> 2.
* Severe allergy to contrast medium.
* Pregnant.
* Patients with intracranial occlusive arteriosclerotic disease or extra or intracranial dissection.
* Documented allergy to acetylsalicylic acid or Tirofiban.
* Personal history of platelet penia (Platelets \<100,000)
* Concomitant anticoagulant treatment with presence of International Normalized Ratio (INR) \> 1.7 in case of anti-vitamin K treatment or taking direct oral anticoagulant \<48 hours ago)
* Medical history of the patient that carries a high risk of bleeding according to the investigator's criteria.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
100 Years
Study:
NCT05225961
Study Brief:
Protocol Section:
NCT05225961